GlobeNewswire

Clariant AG: Construction of Clariant's sunliquid® plant in Romania on track for completion by the end of 2021

Share
  • Construction continues with over 650 workers on site operating in full compliance with all COVID-19 pandemic precaution measurements
  • Majority of large key production equipment has already been installed
  • Recruitment and training of plant operators and other local staff members in progress

Muttenz, December 2, 2020– Clariant, a focused, sustainable and innovative specialty chemical company, today announced that it is making good progress with the construction of its sunliquid® cellulosic ethanol production plant in Podari, in the southwestern part of Romania. While the COVID-19 pandemic continues to present a challenging situation, Clariant’s team was able to ensure that work on the construction site continues while fully complying with all pandemic precaution regulations as established by the Romanian authorities.

“It is truly impressive to see how our project team as well as all local partners have been able to keep this important construction project running while ensuring everyone’s safety and health during the COVID-19 pandemic. Once completed, this sunliquid® cellulosic ethanol production plant will be a cornerstone of our continuing transformation into a leading specialty chemicals company and another proofpoint of our commitment to innovation and sustainability,” said Hans Bohnen, Clariant’s Chief Operating Officer.

The sunliquid® plant receives more than EUR 40 million in funding from the European Union¹ and is constructed on a 10-hectare area in Podari near Craiova in southwestern Romania, from where it has access to a secure regional supply of feedstock and can benefit from the region’s existing logistic and industrial infrastructure. Once operational, the plant will process approx. 250,000 tons of straw to produce 50,000 tons of sunliquid® cellulosic ethanol on an annual basis. This is an advanced, truly sustainable, and carbon-neutral biofuel that can readily be blended into conventional fuel and be used in today's car infrastructure.

"Over the past months, several milestones have been reached on the construction site while also achieving the installation of the majority of large key equipment. This puts us on track to complete the construction by the end of 2021, after which start-up and production will commence. We are proud to see already the substantial benefits that our investment is bringing to the Podari region and look forward to see its impact increase further once the plant is fully staffed and operating at full capacity", says Christian Librera, Vice President and Head of Business Line Biofuels and Derivatives at Clariant.

Clariant is also making headway with the recruitment and training of staff members for its sunliquid® project in Romania. The company’s local employee population is expanding rapidly, with a total of 26 people so far. These team members benefit from a comprehensive training program in Germany and Romania. They started their training at the pre-commercial sunliquid® plant in Straubing, Germany, followed by training sessions in collaboration with the University of Craiova, a renowned educational center in the Southwest of Romania. In the long-term, up to 100 staff members will be directly employed in the plant, while about 300 jobs will be created in connecting businesses, e.g., the collection, storage, and transportation of the feedstock.

On the Moleculist Blog on Clariant’s website, the successful path that has taken the sunliquid® technology platform from development and testing in Bavaria, Germany to the first-of-its-kind commercial facility in Podari, Romania is presented in greater detail.


CORPORATE MEDIA RELATIONSINVESTOR RELATIONS





Jochen Dubiel

Phone +41 61 469 63 63
jochen.dubiel@clariant.com
Maria Ivek

Phone +41 61 469 63 73
maria.ivek@clariant.com






Claudia Kamensky

Phone +41 61 469 63 63
claudia.kamensky@clariant.com
Alexander Kamb

Phone +41 61 469 63 73
alexander.kamb@clariant.com






Thijs Bouwens

Phone +41 61 469 63 63
Thijs.bouwens@clariant.com





Follow us on Twitter, Facebook, LinkedIn, Instagram.



www.clariant.com



Clariant is a focused, sustainable and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2019, the company employed a total workforce of 17 223. In the financial year 2019, Clariant recorded sales of CHF 4.399 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is based on five pillars: focus on innovation and R&D, add value with sustainability, reposition portfolio, intensify growth, and increase profitability.

www.sunliquid.com
www.clariant.com/romania

sunliquid® is an innovative biotechnological method for manufacturing cellulosic ethanol from agricultural residues such as cereal straw, corn stover or sugar cane bagasse. In the completely integrated process, highly optimized, raw material-specific biocatalysts decompose cellulose and hemicellulose in high yields under stable processing conditions into fermentable sugar. The process-integrated production of the biocatalysts offers flexibility and reduces production costs. In the next step, an optimized fermentation organism simultaneously converts C5 and C6 into ethanol with high yields and short reaction times. A highly optimized purification process is instrumental in enabling all the energy required for the process to be derived from the process byproducts like insoluble lignin. Since July 2012, Clariant has been operating a precommercial plant in Straubing, Germany, which produces up to 1,000 metric tons of cellulosic ethanol every year, confirming technical and economic performance. In September 2018, Clariant broke ground for its first-of-its-kind commercial facility in Podari, Romania, where the construction is currently underway. Clariant licenses its sunliquid® technology platform globally. So far, four license agreements have been concluded with renowned industry players in Slovakia, Poland, Bulgaria and China.

¹The project receives funding from the European Union's Seventh Framework Program for research, technological development and demonstration under Grant Agreement no. 322386 (SUNLIQUID) and from the Bio-Based Industries Joint Undertaking under the European Union's Horizon 2020 research and innovation program under Grant Agreement no. 709606 (LIGNOFLAG).

Attachments


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform22.1.2021 14:00:00 CETPress release

Funded by Amgen, Astellas, Bristol Myers Squibb, GSK, Janssen, Lilly, Pfizer, Roche, Sanofi and Takeda The companies will support the rollout of a cloud-based platform with the potential to transform the way the biopharma industry communicates and exchanges information with health authorities worldwide. BURLINGAME, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Ten of the world’s leading biopharmaceutical companies today announced the formation of a new non-profit corporation, Accumulus Synergy, Inc., which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a cloud-based platform to facilitate data and information sharing with the potential to transform the way the biopharmaceutical industry interacts with health authorities. The common-platform approach to data sharing aims to make the regulatory process more efficient

Corr: SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 13:23:24 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Korr: SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 13:23:24 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

PCI Biotech to present at RNA Therapeutics Virtual Conference22.1.2021 12:04:15 CETPress release

Oslo (Norway), 22 January 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the 12th Annual RNA Therapeutics Virtual Conference, a UK based online event taking place February 10-11, 2021. The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations. PCI Biotech is also a sponsor of the event. On Wednesday, February 10, 2021 at 13:10pm (CET), Dr. Anders Høgset, CSO, will present an overview of PCI Biotech’s proprietary platform technology, focusing on the delivery of RNA molecules, including the most recent data on the use of the fimaNAc delivery technology in the exciting field of RNA based therapies. The presentation slides will be made available t

SpareBank 1 SMN: Invitasjon til resultatpresentasjon, 4. kvartal 202022.1.2021 10:47:43 CETPressemelding

SpareBank 1 SMN inviterer til presentasjon av resultatene for 4. kvartal 2020. Tid: Fredag, 5. februar, kl. 08:00 Sted: Webinar Påmelding innen 4. februar via følgende link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 Presentasjonen holdes av konsernsjef Jan-Frode Janson og finansdirektør Kjell Fordal. Det vil også bli holdt et webinar på engelsk samme dag klokken 15:15. Påmelding til den engelske presentasjonen innen 4. februar kan gjøres her: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Spørsmål til begge presentasjoner kan sendes til ir@smn.no. Resultatet publiseres 5. februar klokken 07:00 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

SpareBank 1 SMN: Presentation of 4th Quarter 2020 accounts22.1.2021 10:47:43 CETPress release

SpareBank 1 SMN is presenting 4th quarter 2020 financial results. Time: Friday 5 February at 08:00 AM CET Place: Webinar Please register by 4 February on the link below: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B79474450427340 The presentation will be held in Norwegian by group CEO Jan-Frode Janson and CFO Kjell Fordal. We will also host a Global Investor Webinar in English on the same day at 3:15 PM CET. Please register by 4 February on the following link: http://epost.sparebank1.no/public/event/RegistrationForm/42445A4B794041504B7040 Questions to the management in relation to both presentations can be sent to ir@smn.no. The results will be published on 5 February at 7:00 AM CET. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)